Q: In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.
An injection for double chin reduction developed by Kythera Biopharmaceutical Inc was unanimously backed by an independent panel of experts on Monday, bringing the drug a step closer to approval by the U.S. Food and Drug Administration. 
  
 Kythera's stock has nearly tripled since it went public in 2012 as investors bet on what could be the first approved drug in the United States to reduce localized fat deposits. 
  
 The FDA typically accepts the panel's recommendations. 
  
 The drug, ATX-101, is a formulation of synthetically derived deoxycholic acid, which destroys fat under the chin, leaving surrounding tissue largely unaffected. 
  
 Other injectables, such as Allergan Inc's Botox and dermal fillers are normally used to smoothen areas of the face. 
  
 Fat removal involves more radical procedures - limited to surgeries performed under general anesthesia and liposuction - and higher costs. 
  
 Submental, or below the chin, liposuction costs between $2,700-$5,175, according to the American Society for Dermatologic Surgery. 
  
 Kythera has not revealed its pricing plans for the injection. 
  
 Submental fat, known colloqially as a "double chin" can be caused by a plethora of factors including genetics and lifestyle, and can be resistant to diet and exercise. 
  
 The drug is widely expected to win approval by May 13, when the FDA is scheduled to make its final decision. 
  
 Analysts estimate it will generate at least half a billion dollars in peak U.S. sales. 
  
 Makers of dermatologic and aesthetic drugs, including Nestle SA's Galderma, Allergan Inc, and Johnson & Johnson will likely find ATX-101 attractive and could look to acquire rights to the drug or offer to buy the company, Cowen & Co's Ken Cacciatore said in a client note. 
  
 Kythera's stock was halted on Monday, but had jumped about 25 percent on Thursday when an FDA staff review concluded that the drug's benefits outweighed its risks. 
  
 The stock closed at $53.13 on Friday. 
  
 The drug is also being reviewed by Canadian and Swiss regulators. 
  
 Last year, Kythera regained rights to the market the drug outside the United States and Canada from a unit of Germany's Bayer AG. 
  
 Westlake Village, California-based Kythera entered into separate license agreements last month with Actelion Ltd and the University of Pennsylvania to develop a potent approach to treat hair loss. (bit.ly/1Ml86Zv) 
  
 (Editing by Savio D'Souza and Ted Kerr) ||||| Health FDA panel recommends approval of injections to get rid of double chin March 10, 2015 at 5:29 PM ET 
  
 It sounds almost too good to be true – injections of a drug that melt fat away. Could it mean an end to the dreaded selfie double-chin? 
  
  
  
 Dermatologists seem to think so, and so does a panel advising the Food and Drug Administration. They voted unanimously this week to approve a tiny biotech company’s drug for a very specific and targeted use of its fat-busting drug—to get rid of double chins. 
  
 Kythera has been working on the drug, simply known as ATX-101, for years. Now, clinical trials have shown it’s safe, and makes people happier with their double chins. 
  
 If approved, it could be offered as an alternative to surgery, says Dr. Susan Weinkle, a dermatologist in Bradenton, Florida, who helped test the drug in patients. The FDA usually follows the advice of its committees, although not always. 
  
 “There no other FDA-approved drug like it at all. There is nothing on the market,” Weinkle told NBC News. 
  
 ATX-101 is a specially formulated version of a natural compound found in the body called deoxycholic acid. It’s produced as part of the digestive process and its job is to break down fat. 
  
 Kythera Biopharmaceuticals 
  
 “It causes fat cells to rupture,” Weinkle said. “When you are born you have a certain number of fat cells. During life, these fat cells can be either skinnier or fatter. When you cause a fat cell to rupture, that cell is gone forever.” 
  
 California-based Kythera (pronounced KEE-ther-ah) hopes to use the drug to position itself as a medical “aesthetics” company – think cosmetic procedures akin to the widespread use of Botox. The company’s name comes from one of two Greek islands that claimed to be the birthplace of Aphrodite, Greek goddess of love and beauty. 
  
 It’s carefully sought approval for ATX-101 for a very limited condition. 
  
 Medically, it’s called submental fat. Most people know it as a double chin, and Weinkle says the treatment involves a series of injections one month apart. They’d be done in the doctor’s office. 
  
 It’s not painless—most patients reported bruising, pain, numbness and swelling. A few reported scarier problems such as trouble swallowing, although it didn’t last long. Surgery often causes more serious side-effects. 
  
 And it’s definitely not for everyone, cautions Dr. Michael Edwards, president of the Society for Aesthetic Plastic Surgery. 
  
  
  
 “My biggest concern is once it is approved, people will start to use it for other areas of the face or for larger volumes (of fat) in other areas,” Edwards told NBC News. 
  
 Weinkle says it takes some skill and training to perform the injections properly. Patients are going to want a very even reduction of fat, there are delicate nerves in the area to be avoided, and the injections must go to a certain depth. “You have to understand the anatomy of the area,” she said. 
  
  
  
 But once a drug is approved by the FDA and on the market, any physician may prescribe it as he or she wishes. FDA does not consider how doctors may use a drug in their practices. That raises the question of spot reduction clinics. 
  
 Edwards worries patients will flock to untrained practitioners who may try to dilute the drug to use it on a larger area—something that could lead to lumpy results at best, and perhaps complications. He stresses that people should only seek treatments from board certified experts who are trained to do the procedure in question. 
  
 “If it were my face, or my wife’s face, or my mother’s face I would want somebody who knows what they are doing,” Edwards said. 
  
 The American Society for Aesthetic Plastic Surgery plans to release a report Wednesday showing a 42 percent increase over the past year in nonsurgical fat reduction treatments. The most popular surgical procedure last year? Liposuction with 342,494 procedures performed. It costs, on average, around $3,000. 
  
 “People go through all sorts of shenanigans to get their neck to look the way they want." 
  
 Many of those are for the double chin. 
  
 “People go through all sorts of shenanigans to get their neck to look the way they want,” Edwards said. 
  
 Nonsurgical alternatives include CoolSculpting, Vaser Shape and Liposonix, with more than 135,000 of these procedures done last year. Edwards said they work somewhat well, in carefully chosen patients, but none produce dramatic results. 
  
 The same would be true for ATX-101. 
  
 “And a lot depends on the patient. It’s not a weight loss treatment,” Weinkle stresses. “This is not for decreasing your overall BMI (body mass index),” she said. 
  
 Some patients with very fat necks might end up with wattles of loose skin, and patients whose skin isn’t naturally elastic might also end up with “turkey neck”. 
  
 But the process itself appears to be safe, at least when the injection is used to remove very small amounts of fat. The body seems to absorb and excrete the busted-up fat cells, the studies show. 
  
 “I personally think it is going to be very exciting,” says Weinkle, who plans to offer the procedure in her office. The company declined any comment and hasn't released any information about potential pricing. 
  
 “I can’t wait to inject myself. Which of us doesn’t have a little bit of fat under our chin?” 
  
  ||||| Kythera Biopharmaceuticals Inc. said on Monday that a Food and Drug Administration advisory panel voted unanimously to recommend approval of the company’s injectable drug to treat adult submental fat, or what is commonly known as a double chin. 
  
 The treatment would be a nonsurgical option for double chin, which the company calls a much-cited but undertreated aesthetic complaint that results in an older and heavier facial appearance, and it would represent a new product category. 
  
 ... |||||
A:
A biotech company thinks it has the answer to double chins—an injection, of course. An FDA advisory panel has cleared a treatment from Kythera Pharmaceuticals called ATX-101, reports the Wall Street Journal. If the FDA goes along with the recommendation, as it usually does, the injections could win final approval in May and be available from dermatologists a month or two later. Reuters offers this explanation of how it works: The drug "is a formulation of synthetically derived deoxycholic acid, which destroys fat under the chin, leaving surrounding tissue largely unaffected." It would be the first such treatment designed to remove specific fat deposits, and the company's stock has tripled since it went public in 2012. Kythera hasn't released pricing, but the treatment—actually a series of shots that would be given in a doctor's office—would presumably be cheaper than than below-the-chin liposuction, which can cost more than $5,000. “My biggest concern is once it is approved, people will start to use it for other areas of the face or for larger volumes (of fat) in other areas,” the president of the Society for Aesthetic Plastic Surgery tells NBC News. In the wrong hands, it could make things worse, he adds. The FDA panel gave the green light after 19 clinical trials involving 2,600 patients. (When the Quaker Oats guy got a makeover, his double chin went away.)